Cabozantinib

Excerpt

A 50-year-old man developed rash following treatment with cabozantinib for lung adenocarcinoma. The man, who had left upper lobe lung adenocarcinoma, was treated with cisplatin and gemcitabine. Half year later, he started receiving unspecified systemic therapy. He did not receive chemotherapy due intolerance. A polymerase chain reaction revealed positive KIF5B/RET fusion gene. Subsequently, on 10 June 2017, he started receiving treatment with oral cabozantinib 140mg once daily for about nine months. During cabozantinib therapy, he developed grade II rash [duration of treatment to reaction onset and outcome not stated]. …